ArticleBMC nursing2026
Design and development of a mobile chemotherapy drug guide (ChemoNurse) for oncology nurses: a feasibility and usability pilot study.
Article in BMC nursing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to design, develop, and evaluate the feasibility of a mobile chemotherapy drug guide (ChemoNurse) tailored for oncology nurses. The evaluation focused on feasibility, usability, and acceptability outcomes. ChemoNurse includes drug preparation, storage methods, administration routes, administration duration, dosage calculation, side effects, patient education, and symptom management.
methodsThis feasibility study was conducted between August 1, 2023, and August 1, 2024, with 34 oncology nurses from the Turkish Oncology Nursing Society. The Standard Protocol Items: Recommendations for Interventional Trials checklist was utilized. The RE-AIM framework was used to guide the evaluation of early implementation outcomes, particularly feasibility, usability, and acceptability. The evaluation framework integrates usability, perceived usefulness, acceptability, and feasibility. The Information Form, ChemoNurse Evaluation Form, Mobile Application Usability Scale, Satisfaction Scale, and semi-structured interview form were used for data collection.
resultsThe nurses' mean age was 32.79 ± 6.55 years, 91.2% female, and most had over ten years of professional experience. The evaluation of ChemoNurse's usability demonstrated high acceptance and perceived usefulness among oncology nurses. 94.1% of participants rated the application as easy to use, and 100% of participants reported that the content was understandable and clinically relevant. Additionally, 85.3% of participants considered the drug guide content clinically sufficient, and 91.2% confirmed that the application met their clinical needs. The application was perceived as cost-effective by all participants, and 97.1% of participants indicated they would continue using ChemoNurse in clinical practice. The Mobile Application Usability Scale results further supported these findings, with 91.2% of nurses scoring above 200 and a mean usability score of 246.76 ± 38.13.
conclusionsPreliminary evidence suggests that ChemoNurse is usable and acceptable for supporting oncology nurses' point-of-care access to chemotherapy information within this pilot sample; larger studies are needed to confirm its clinical impact. ChemoNurse demonstrated promising feasibility, usability, and acceptability within this pilot sample. Future studies with objective outcome measures are needed to evaluate its potential perceived usefulness and implementation feasibility in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.